171 results
Page 5 of 9
8-K
EX-99.1
epnxzemxv1a29qr
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
3an lxnl4pw4j2ro
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
o6tx2wix09y14 m5ryx
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
65b5x f6d2l
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
ddl3cw2qhegt289or
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-10.1
1f4cgrn4w4u owh
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
424B5
qrhg 3yg8z07
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-99.1
ciczskyeyl8rc6b3
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
5aap3 lpe
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
las7ai
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
aesxlzog19tvzq
8 Oct 20
Regulation FD Disclosure
5:01pm